Regulator of
G-protein signaling
protein 19 (RGS19), also known as Gα-interacting
protein (GAIP), acts as a
GTPase accelerating
protein for Gαz as well as Gαi/o subunits. Interactions with GAIP-interacting
protein N-terminus and GAIP-interacting
protein C-terminus (GIPC) link RGS19 to a variety of intracellular
proteins. Here we show that RGS19 is abundantly expressed in human
neuroblastoma SH-SY5Y cells that also express µ- and δ-
opioid receptors (MORs and DORs, respectively) and
nociceptin receptors (NOPRs). Lentiviral delivery of
short hairpin RNA specifically targeted to RGS19 reduced RGS19
protein levels by 69%, with a similar reduction in GIPC. In RGS19-depleted cells, there was an increase in the ability of MOR (
morphine) but not of DOR [(4-[(R)-[(2S,5R)-4-allyl-2,5-dimethylpiperazin-1-yl](3-methoxyphenyl)methyl]-
N,N-diethylbenzamide (
SNC80)] or NOPR (
nociceptin) agonists to inhibit
forskolin-stimulated
adenylyl cyclase and increase
mitogen-activated protein kinase (MAPK) activity. Overnight treatment with either MOR [D-Ala, N-Me-
Phe, Gly-ol(5)-
enkephalin (
DAMGO) or
morphine] or DOR (D-Pen(5)-
enkephalin or
SNC80) agonists increased RGS19 and GIPC
protein levels in a time- and concentration-dependent manner. The MOR-induced increase in RGS19
protein was prevented by pretreatment with
pertussis toxin or the
opioid antagonist naloxone.
Protein kinase C (PKC) activation alone increased the level of RGS19 and inhibitors of PKC 5,6,7,13-tetrahydro-13-methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4-c]
carbazole-12-propanenitrile and
mitogen-activated protein kinase kinase 1 2-(2-amino-3-methoxyphenyl)-4H-chromen-4-one, but not
protein kinase A (
H89), completely blocked
DAMGO-induced RGS19
protein accumulation. The findings show that RGS19 and GIPC are jointly regulated, that RGS19 is a
GTPase accelerating
protein for MOR with selectivity over DOR and NOPR, and that chronic MOR or DOR agonist treatment increases RGS19 levels by a PKC and the MAPK pathway-dependent mechanism.